Lilly trades at a premium to Ozempic maker Novo as obesity drugs boom. Here’s why, analyst says
Does Eli Lilly deserve to commerce at a premium to Novo Nordisk shares? For Deutsche Bank analyst James Shin, the ...
Does Eli Lilly deserve to commerce at a premium to Novo Nordisk shares? For Deutsche Bank analyst James Shin, the ...
Unlock the Editor’s Digest totally freeRoula Khalaf, Editor of the FT, selects her favorite tales in this weekly e-newsletter.A ransomware ...
© 2022 Apkconnex- All Right are reserved